Severe Asthma ManagementÂ
Severe asthma patients account for as much as 60% of all asthma healthcare costs, and proper management of severe disease is essential.
Severe asthma patients account for as much as 60% of all asthma healthcare costs, and proper management of severe disease is essential.
Severe asthma patients account for as much as 60% of all asthma healthcare costs, and proper management of severe disease is essential.
Read MoreA monoclonal antibody, mepolizumab, decreased asthma attacks by 27% in Black and Hispanic children and adolescents who have a form of severe asthma.
Read MoreThe approval makes Nucala the first and only targeted biologic treatment to be approved for patients with Hypereosinophilic Syndrome in the US.
Read MoreHypereosinophilic Syndrome involves overproduction of eosinophils, which can cause inflammation and organ damage that lead to respiratory and cardiac problems.
Read MoreThe US FDA has approved Nucala (mepolizumab) for use in children as young as six years old who are living with severe eosinophilic asthma.
Read MoreThe US FDA has approved two new methods for administering Nucala (mepolizumab), including an autoinjector and a pre-filled safety syringe that can be self-administered by patients or caregivers.
Read MoreUS regulatory advisors are questioning the effectiveness of GlaxoSmithKline’s biologic Nucala as a treatment for patients experiencing a sudden worsening of COPD. Nucala (mepolizumab) is a monoclonal antibody – already...
Read MoreSevere asthma patients who are uncontrolled despite receiving Xolair (omalizumab) experienced improved asthma control when switched to Nucala (mepolizumab), according to GlaxoSmithKline.
Read MoreThe FDA has approved Nucala (mepolizumab) as the first targeted treatment for eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss syndrome.
Read MoreMepolizumab (Nucala) is already approved for use in the US as an add-on maintenance treatment for patients with severe asthma aged 12 years and older.
Read MoreMedPage Today is reporting mixed results for mepolizumab (Nucala) as an add-on treatment for patients with eosinophilic phenotype COPD.
Read MoreThe GlaxoSmithKline asthma biologic mepolizumab (Nucala) improved quality of life in asthma patients, reports MedPage Today. Mepolizumab has been shown to reduce exacerbation rates and dependency on oral corticosteroid use in...
Read MoreNucala improved health-related quality of life and lung function in severe asthma patients whose disease is driven by eosinophilic inflammation.
Read MoreGlaxoSmithKline will provide updates on research across its respiratory portfolio at the European Respiratory Society International Congress.
Read MoreSeveral new pharmacological treatments for COPD and asthma have appeared on the respiratory market in the past year but what are the advantages these new generation pharmaceuticals?
Read MoreNew safety and efficacy data for Nucala (mepolizumab) shows that the risk/benefit profile generated through the pivotal studies for Nucala was maintained over an extended 52-week period.
Read MoreNucala (mepolizumab) is now available by prescription in the United States, according to manufacturer GlaxoSmithKline.
Read MoreThe FDA has approved the drug mepolizumab (Nucala) for treating severe asthma in patients 12 years and older with an eosinophilic phenotype.
Read MoreAn FDA advisory committee has voted in favor of approving Nucala (mepolizumab, GlaxoSmithKline) for the treatment of severe asthma in adults 18 years and older.
Read More